• Citer

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.

par Moens, Annick;van der Woude, Janneke CJ;Julsgaard, Mette;Humblet, Evelien;Sheridan, Juliette;Baumgart, Daniel;Gilletta De Saint-Joseph, Cyrielle;Nancey, Stéphane;Rahier, Jean François;Bossuyt, Peter;Cremer, Anneline ;Dewit, Sophie;Eriksson, C;Hoentjen, Frank;Krause, Thomas;Louis, Edouard;Macken, Elisabeth;Milenkovic, Zoran;Nijs, Jochen;Posen, Annelies;Van Hootegem, Anneleen;Van Moerkercke, W.;Vermeire, Séverine;Bar-Gil Shitrit, Ariella;Ferrante, Marc
Référence Alimentary pharmacology & therapeutics, 51, 1, page (129-138)
Publication Publié, 2020-01-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse.